🇺🇸 FDA
Pipeline program

GS030-DP, GS030-DP, GS030-DP

GS030_CLIN_001

Phase 2 small_molecule active

Quick answer

GS030-DP, GS030-DP, GS030-DP for Retinitis Pigmentosa is a Phase 2 program (small_molecule) at GenSight Biologics S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GenSight Biologics S.A.
Indication
Retinitis Pigmentosa
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials